Efficacy profiling innovation in novel pain therapeutics discovery. The purpose of this project is to bring innovation into the methods used for selecting novel compounds with high potential for progression into development as highly effective pain-killers for improving the relief of chronic pain. This will result in new pain-killers that are highly effective without producing unpleasant side-effects.
Industrial Transformation Training Centres - Grant ID: IC180100021
Funder
Australian Research Council
Funding Amount
$4,163,359.00
Summary
ARC Training Centre for the Development of Tools for Fragment Based Design. The ARC Training Centre for the Development of Tools for Fragment Based Design aims to inspire the next generation of drug discovery research leaders. It plans to provide direct experience with industry partners, training and master classes in early stage drug-discovery from industry experts. The Centre is expected to accelerate research translation and industry engagement by providing an efficient strategy for the scree ....ARC Training Centre for the Development of Tools for Fragment Based Design. The ARC Training Centre for the Development of Tools for Fragment Based Design aims to inspire the next generation of drug discovery research leaders. It plans to provide direct experience with industry partners, training and master classes in early stage drug-discovery from industry experts. The Centre is expected to accelerate research translation and industry engagement by providing an efficient strategy for the screening of a biological target and early medicinal chemistry for optimisation. The expected outcome of the Centre is to equip the trainees with the skills to make key contributions to the sustainability and growth of the sector and to provide significant capacity to address global challenges for 21st century pharmaceutical innovation.Read moreRead less
Refinement And Delivery Of Synthetic Compounds That Specifically Alter Muscle Contraction. The project has broad benefits for the nation and the community. Cutting edge research at the molecular level, done within Australia, will benefit Australian scientists and research in general. The discovery of drugs that will be developed by the Australian Pharmaceutical Industry will benefit the Australian Industry sector and will have spin-offs for the racing industry, livestock industry (lean meat) an ....Refinement And Delivery Of Synthetic Compounds That Specifically Alter Muscle Contraction. The project has broad benefits for the nation and the community. Cutting edge research at the molecular level, done within Australia, will benefit Australian scientists and research in general. The discovery of drugs that will be developed by the Australian Pharmaceutical Industry will benefit the Australian Industry sector and will have spin-offs for the racing industry, livestock industry (lean meat) and for rural industry (insecticides). In addition, expansion of the outcomes of the project into preclinical development will strengthen the Australian bioscience sector. Thus the project will eventually benefit the Australian industry sector. The project will have further benefits for education and training. Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH220100017
Funder
Australian Research Council
Funding Amount
$4,808,669.00
Summary
ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The progra ....ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100016
Funder
Australian Research Council
Funding Amount
$3,123,492.00
Summary
ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therap ....ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therapeutics. The use of an individual patient’s cellular and molecular research findings will ultimately enable personalised diagnostic and therapeutic decisions.Read moreRead less
Pharmacology Of Potential Anti-Tumour Agents: Iron Chelators Of The BpT Class
Funder
National Health and Medical Research Council
Funding Amount
$585,455.00
Summary
Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Renewal, we will perform pharmacological and preclinical studies to promote the development of BpT chelators as novel anti-tumour agents.
A genomic and phenomic investigation of a mitochondrial glutathione transferase. The aim of this study is to understand of the genomics, structure and function of glutathione transferase Kappa (GSTK), a novel GST found in mitochondria. The investigations will achieve several outcomes. (1)an understanding of the organisation of GSTK gene(s) in humans and mice; (2) determination of the role of GSTK in mitochondria, by investigating the phenotype of knockout mice; (3) determination of the crysta ....A genomic and phenomic investigation of a mitochondrial glutathione transferase. The aim of this study is to understand of the genomics, structure and function of glutathione transferase Kappa (GSTK), a novel GST found in mitochondria. The investigations will achieve several outcomes. (1)an understanding of the organisation of GSTK gene(s) in humans and mice; (2) determination of the role of GSTK in mitochondria, by investigating the phenotype of knockout mice; (3) determination of the crystal structure of human GSTK; (4) An understanding of GSTK's substrate specificity, reaction kinetics and structure/function relationships. Since GSTK is confined to mitochondria, and may not be related to other GSTs, we may also identify novel functionsRead moreRead less
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Molecular Interactions of Chemical Agents with Ion-Channel Proteins. With a minimal number of functional units (proteins) viruses are able to replicate. All of these proteins are possible antiviral targets. In this project we wil1 focus on a short protein called Vpu found in membranes of the HIV-1 virus and aim to analyse the interaction of potential pore blocking compounds. It is essential to know exactly where they sit and how the overall structure of Vpu is affected. For this enterprise we wi ....Molecular Interactions of Chemical Agents with Ion-Channel Proteins. With a minimal number of functional units (proteins) viruses are able to replicate. All of these proteins are possible antiviral targets. In this project we wil1 focus on a short protein called Vpu found in membranes of the HIV-1 virus and aim to analyse the interaction of potential pore blocking compounds. It is essential to know exactly where they sit and how the overall structure of Vpu is affected. For this enterprise we will use nuclear magnetic resonance (NMR) spectroscopy. This information will serve as a springboard for future investigations of virus membrane proteins.
Read moreRead less
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revol ....ARC Centre of Excellence in Convergent Bio-Nano Science and Technology. The CoE in Convergent Bio-Nano Science &Technology comprises a multi-disciplinary team focused on research aiming to understand and control the interface of materials with biological systems. The Centre will exploit knowledge of the bio-nano interface to design materials that transport and deliver vaccines, drugs and gene therapy agents, and to design new diagnostic agents and devices. Nanomedicines are on the cusp of revolutionizing diagnosis and therapy in many diseases. The CoE will be the focus of bio-nano research activity in Australia, uniting universities, research agencies, institutes and companies. The expected outcomes are better diagnostic and therapeutic tools designed via an enhanced understanding of the bio-nano-interface.Read moreRead less